首页> 美国卫生研究院文献>BMC Cancer >A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

【2h】

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

机译：每日Carboplatin Plus辐射的II期研究然后是III阶段非小细胞肺癌患者PS 2高达74岁PS 0或1患者从75年的患者：NEJ039A（正在进行中的试验）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Design and protocol of this study

机译：本研究的设计与协议

著录项

期刊名称 BMC Cancer
作者
Kyoichi Kaira; Atsuto Mouri; Shingo Kato; Kenichi Yoshimura; Hiroshi Kagamu; Kunihiko Kobayashi;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：Durvalumab;化学疗法;局部晚期非小细胞肺癌;老年人;PS 2;Carboplatin;免疫检查点抑制剂;PD-L1抗体;

相似文献

外文文献
中文文献
专利

1. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. [J] . Langer CJ, OByrne KJ, Socinski MA, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第6期

机译：III期试验比较了紫杉醇poliglumex（CT-2103，PPX）联合卡铂与标准紫杉醇和卡铂在未接受化疗的PS 2初发性晚期非小细胞肺癌患者中的治疗。
2. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. [J] . Langer CJ, OByrne KJ, Socinski MA, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第6期

机译：III期试验比较了紫杉醇poliglumex（CT-2103，PPX）联合卡铂与标准紫杉醇和卡铂在未接受化疗的PS 2初发性晚期非小细胞肺癌患者中的治疗。
3. 9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group (WJTOG) 0105 [J] . N.Katakami, M.Satouchi, N.Yamamoto, European Journal of Cancer Supplements . 2009,第2期

机译：9104丝裂霉素/长春地辛/顺铂（MVP）与每周伊立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（CTR）的不可切除的III期非小细胞患者的3期随机研究肺癌（NSCLC）：西日本胸腔肿瘤小组（WJTOG）0105
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531 [O] . Gregory A. Masters, Xiaofei Wang, Lydia Hodgson, -1

机译：具有G-CSF和外周血干细胞的高剂量卡铂和紫杉醇的II期试验然后是III期非小细胞肺癌患者手术和/或胸部辐射：CALGB 9531
7. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress) [O] . Kyoichi Kaira, Atsuto Mouri, Shingo Kato, 2020

机译：每日Carboplatin Plus辐射的II期研究，然后是III阶段非小细胞肺癌患者PS 2高达74岁，PS 0或1患者从75年的患者：NEJ039A（正在进行中的试验）

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

摘要

著录项

相似文献

相关主题

期刊订阅